The role of thiotepa in allogeneic stem cell transplantation in patients with leukemia.

No abstract is available for this paper.

• Publication year

  1999

• Venue

  Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis

• Publication date

  1999-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S0145-2126(99)00112-5PMID 10573141
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Dosing of thioTEPA for myeloablative therapy

  2004cited by this paper
• Thiotepa improves allogeneic bone marrow engraftment without enhancing stem cell depletion in irradiated mice

  1998cited by this paper
• T-cell-depleted allogeneic bone marrow transplantation as postremission therapy for acute myelogenous leukemia: freedom from relapse in the absence of graft-versus-host disease.

  1998cited by this paper
• Tandem high-dose chemotherapy supported by hematopoietic progenitor cells yields prolonged survival in stage IV breast cancer.

  1996cited by this paper
• Busulfan, cyclophosphamide and fractionated total body irradiation for allogeneic marrow transplantation in advanced acute and chronic myelogenous leukemia: phase I dose escalation of busulfan based on targeted plasma levels.

  1996cited by this paper
• Allogeneic transplantation for advanced leukemia: improved short-term outcome with blood stem cell grafts and tacrolimus.

  1996cited by this paper
• Improved single-step PCR assay for sex identification post-allogeneic sex-mismatched BMT.

  1996cited by this paper
• Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation.

  1996cited by this paper
• A study of thiotepa, etoposide and fractionated total body irradiation as a preparative regimen prior to bone marrow transplantation for poor prognosis patients with neuroblastoma.

  1996cited by this paper
• T‐cell‐depleted allogeneic bone marrow transplantation for acute leukaemia using Campath‐1 antibodies and post‐transplant administration of donor's peripheral blood lymphocytes for prevention of relapse

  1995cited by this paper
• T cell depletion by exposure to Campath-1G in vitro prevents graft-versus-host disease.

  1994cited by this paper
• A phase I-II study of high-dose thiotepa, busulfan and cyclophosphamide as a preparative regimen for allogeneic marrow transplantation.

  1994cited by this paper
• Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for marrow transplantation: Risk factors for early regimen-related toxicity

  1994cited by this paper
• Use of paclitaxel (Taxol) in squamous cell carcinoma of the head and neck.

  1993cited by this paper
• Thiotepa, busulfan, and cyclophosphamide: a new preparative regimen for autologous marrow or blood stem cell transplantation in high-risk multiple myeloma.

  1993cited by this paper
• The development of busulfan/cyclophosphamide preparative regimens.

  1993influential reference
• New preparative regimens with diaziquone or cytarabine in combination with busulfan and cyclophosphamide.

  1993cited by this paper
• Malabsorption of vitamin B12 from the intestine in a child with cblF disease: evidence for lysosomal-mediated absorption [letter]

  1992cited by this paper
• Hepatic veno-occlusive disease--liver toxicity syndrome after bone marrow transplantation.

  1992cited by this paper
• Slow response to induction chemotherapy is an indicator of poor survival after bone marrow transplantation for acute lymphoblastic leukemia. The Leukemia Working Party of the European Group of Bone Marrow Transplantation (EBMT).

  1992cited by this paper
• Phase I study of busulfan, cyclophosphamide, and timed sequential escalating doses of cytarabine followed by bone marrow transplantation.

  1992cited by this paper
• Phase I/pharmacokinetic reevaluation of thioTEPA.

  1991cited by this paper
• The Use of Recombinant Human Granulocyte‐Macrophage Colony Stimulating Factor in Autologous Bone Marrow Transplantation

  1991cited by this paper
• Results of T-depleted BMT in chronic myelogenous leukaemia after a conditioning regimen that included thiotepa.

  1991cited by this paper
• N,N',N''-triethylenethiophosphoramide (thio-TEPA) oxygenation by constitutive hepatic P450 enzymes and modulation of drug metabolism and clearance in vivo by P450-inducing agents.

  1991cited by this paper
• New developments in bone marrow transplantation.

  1991cited by this paper
• Enhancement of T cell-depleted bone marrow allografts in mice by thiotepa.

  1990cited by this paper
• High-dose N,N',N"-triethylenethiophosphoramide (thiotepa) with autologous bone marrow transplantation: phase I studies.

  1990cited by this paper
• Escalating doses of etoposide with cyclophosphamide and fractionated total body irradiation or busulfan as conditioning for bone marrow transplantation.

  1989cited by this paper
• Phase I and pharmacokinetic evaluation of thiotepa in the cerebrospinal fluid and plasma of pediatric patients: evidence for dose-dependent plasma clearance of thiotepa.

  1989cited by this paper
• Regimen-related toxicity in patients undergoing bone marrow transplantation.

  1988cited by this paper
• Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen

  1987cited by this paper
• Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen.

  1987cited by this paper
• Critical issues in bone marrow transplantation.

  1987cited by this paper
• Characterization of a panel of highly variable minisatellites cloned from human DNA

  1987cited by this paper
• Hypervariable ‘minisatellite’ regions in human DNA

  1985cited by this paper
• Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide.

  1983cited by this paper
• One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allogeneic marrow transplantation.

  1977cited by this paper
• Toxicity, antitumor activity, and pharmacokinetics of spin-labeled thioTEPA analogs.

  1976cited by this paper
• Toxicity, antitumor activity, and pharmacokinetics of spin-labeled thioTEPA analogs.

  1976cited by this paper
• Nonparametric Estimation from Incomplete Observations

  1958cited by this paper

• Double‐unit unrelated cord blood transplantation for thalassemia major: Comparison with HLA‐identical sibling bone marrow transplantation

  2020cites this paper
• Thiotepa and antithymocyte globulin-based conditioning prior to haploidentical transplantation with posttransplant cyclophosphamide in high-risk hematological malignancies

  2019cites this paper
• Thiotepa, busulfan and fludarabine compared to busulfan and cyclophosphamide as conditioning regimen for allogeneic stem cell transplant from matched siblings and unrelated donors for acute myeloid leukemia

  2018cites this paper
• Title : Thiotepa , busulfan and fludarabine compared to busulfan and cyclophosphamide as conditioning regimen for allogeneic stem cell transplant from matched siblings and unrelated donors for acute myeloid leukemia

  2018cites this paper
• Thiotepa-busulfan-fludarabine compared to busulfan-fludarabine for sibling and unrelated donor transplant in acute myeloid leukemia in first remission

  2017cites this paper
• Safety and efficacy of thiotepa-based conditioning for allogeneic transplantation in AML: a survey from the ALWP of the EBMT

  2017cites this paper
• Thiotepa‐based conditioning for allogeneic stem cell transplantation in acute lymphoblastic leukemia—A survey from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

  2017influential citation
• Interactions of cyclodextrins and their derivatives with toxic organophosphorus compounds

  2016cites this paper
• Thiotepa‐based versus total body irradiation‐based myeloablative conditioning prior to allogeneic stem cell transplantation for acute myeloid leukaemia in first complete remission: a retrospective analysis from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantati

  2016cites this paper
• A phase I/II trial of reduced intensity allogeneic hematopoietic cell transplant for hematologic malignancies using cladribine, thiotepa and rabbit antithymocyte globulin

  2013cites this paper
• Reduced-intensity conditioning with fludarabine and thiotepa for second allogeneic transplantation of relapsed patients with AML

  2013cites this paper
• Radiation-free allogeneic conditioning with fludarabine, carmustine, and thiotepa for acute lymphoblastic leukemia and other hematologic malignancies necessitating enhanced central nervous system activity.

  2012cites this paper
• A novel conditioning regimen improves outcomes in β-thalassemia major patients using unrelated donor peripheral blood stem cell transplantation.

  2012cites this paper
• A fludarabine, thiotepa reduced toxicity conditioning regimen designed specifically for allogeneic second haematopoietic cell transplantation after failure of previous autologous or allogeneic transplantation

  2008cites this paper
• High-dose busulfan, cyclophosphamide, and etoposide does not improve outcome of allogeneic stem cell transplantation compared to BuCy2 in patients with acute myeloid leukemia

  2005cites this paper
• Mixed chimerism is frequent after allogeneic peripheral blood stem cell transplantation with positive CD34 selection, and is not reverted by low doses of donor T‐cells add‐back

  2004cites this paper
• Peripheral Blood Stem Cell Transplantation and Graft-versus-Host Disease: A Case Study

  2002cites this paper
• Cytochrome P450 isozymes 3A4 and 2B6 are involved in the in vitro human metabolism of thiotepa to TEPA

  2002cites this paper